277 related articles for article (PubMed ID: 28859734)
21. Parotid Sebaceous Carcinoma in Patient with Muir Torre Syndrome, Caused by MSH2 Mutation.
Neelakantan IV; Di Palma S; Smith CE; McCoombe A
Head Neck Pathol; 2016 Sep; 10(3):354-61. PubMed ID: 26577210
[TBL] [Abstract][Full Text] [Related]
22. [The tip of the iceberg: multiple cutaneous sebaceous tumor in colon cancer. Muir-Torre syndrome--case report].
Herr G; Szenes M; Hohl G; Vinkler ME; Tüske G; Horváth J; Nagy G; Tihanyi M; Széll M; Nagy N; Gasztonyi B
Orv Hetil; 2015 Jun; 156(24):979-84. PubMed ID: 26051134
[TBL] [Abstract][Full Text] [Related]
23. Reticulated acanthoma with sebaceous differentiation: another sebaceous neoplasm associated with Muir-Torre syndrome?
Shon W; Wolz MM; Newman CC; Bridges AG
Australas J Dermatol; 2014 Nov; 55(4):e71-3. PubMed ID: 23651324
[TBL] [Abstract][Full Text] [Related]
24. Muir-Torre Syndrome with Novel Mutation in the MSH2 Gene.
Ustaoglu E; Agirgol S; Aymelek HS; Turhan EI
Acta Dermatovenerol Croat; 2023 Dec; 31(3):144-147. PubMed ID: 38439724
[TBL] [Abstract][Full Text] [Related]
25. [Lynch syndrome, Muir Torre variant: 2 cases].
Castro-Mujica Mdel C; Barletta-Carrillo C; Acosta-Aliaga M; Montenegro-Garreaud X
Rev Gastroenterol Peru; 2016; 36(1):81-5. PubMed ID: 27131946
[TBL] [Abstract][Full Text] [Related]
26. Somatic MMR gene mutations as a cause for MSI-H sebaceous neoplasms in Muir-Torre syndrome-like patients.
Joly MO; Attignon V; Saurin JC; Desseigne F; Leroux D; Martin-Denavit T; Giraud S; Bonnet-Dupeyron MN; Faivre L; Auclair J; Grand-Masson C; Audoynaud C; Wang Q
Hum Mutat; 2015 Mar; 36(3):292-5. PubMed ID: 25504677
[TBL] [Abstract][Full Text] [Related]
27. The frequency of Muir-Torre syndrome among Lynch syndrome families.
South CD; Hampel H; Comeras I; Westman JA; Frankel WL; de la Chapelle A
J Natl Cancer Inst; 2008 Feb; 100(4):277-81. PubMed ID: 18270343
[TBL] [Abstract][Full Text] [Related]
28. Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.
Ponti G; Pellacani G; Ruini C; Percesepe A; Longo C; Mandel VD; Crucianelli F; Gorelli G; Tomasi A
Fam Cancer; 2014 Dec; 13(4):553-61. PubMed ID: 24969397
[TBL] [Abstract][Full Text] [Related]
29. Multiple benign adnexal tumours: Anything but benign.
McCarthy RL; Thomas CL; Isaacs F
Australas J Dermatol; 2019 Aug; 60(3):234-236. PubMed ID: 30671930
[TBL] [Abstract][Full Text] [Related]
30. MSH6 mutation in a family affected by Muir-Torre syndrome.
Kacerovska D; Cerna K; Martinek P; Grossmann P; Michal M; Ricar J; Kazakov DV
Am J Dermatopathol; 2012 Aug; 34(6):648-52. PubMed ID: 22814321
[TBL] [Abstract][Full Text] [Related]
31. Synchronous gastric and sebaceous cancers, a rare manifestation of MLH1-related Muir-Torre syndrome.
Svec J; Schwarzová L; Janošíková B; Stekrová J; Mandys V; Kment M; Vodička P
Int J Clin Exp Pathol; 2014; 7(8):5196-202. PubMed ID: 25197397
[TBL] [Abstract][Full Text] [Related]
32. Muir-Torre Syndrome: expanding the genotype and phenotype--a further family with a MSH6 mutation.
Murphy HR; Armstrong R; Cairns D; Greenhalgh KL
Fam Cancer; 2008; 7(3):255-7. PubMed ID: 18236172
[TBL] [Abstract][Full Text] [Related]
33. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy.
Landis MN; Davis CL; Bellus GA; Wolverton SE
J Am Acad Dermatol; 2011 Nov; 65(5):1054-1058.e1. PubMed ID: 21550136
[TBL] [Abstract][Full Text] [Related]
34. Muir-Torre Syndrome With a Frame-shift Mutation in the MSH2 Gene: A Rare Case Report and Literature Review.
Chen Q; Wang M; Xu Z; Wang M; Jin S; Tian S; Xiao S
Int J Gynecol Pathol; 2020 Mar; 39(2):136-140. PubMed ID: 32039937
[TBL] [Abstract][Full Text] [Related]
35. Muir-Torre Syndrome: A Case Report in a Woman Without Personal Cancer History.
Torre K; Ricketts J; Dadras SS
Am J Dermatopathol; 2019 Jan; 41(1):55-59. PubMed ID: 29933315
[TBL] [Abstract][Full Text] [Related]
36. Muir-Torre syndrome: a case of unusual coexisting genetic mutations.
Cino D; Drumm C; Sheahan K; D'Arcy C; Nolan N; Hoti E; Winter D; O'Duffy F; Dolan R; Moriarty B
Clin Exp Dermatol; 2022 Mar; 47(3):602-604. PubMed ID: 34762321
[TBL] [Abstract][Full Text] [Related]
37. Metachronous occurrence of colorectal cancer in a muir-torre syndrome patient presenting with recurrent sebaceous adenoma of the eyelid: case report and updated review of the literature.
Agiannidis C; Pana ZD; Molyva D; Kalokasidis K; Mixiou M
J Cutan Med Surg; 2012; 16(6):394-9. PubMed ID: 23149194
[TBL] [Abstract][Full Text] [Related]
38. Ocular Adnexal Adenomatoid Sebaceous Gland Hyperplasia: A Clinical and Immunopathologic Analysis in Relation to the Muir-Torre Syndrome.
Jakobiec FA; Cortes Barrantes P; Milman T; Lee NG; Fay A
Ophthalmic Plast Reconstr Surg; 2020; 36(1):e6-e12. PubMed ID: 31593035
[TBL] [Abstract][Full Text] [Related]
39. Tumor mutational signatures in sebaceous skin lesions from individuals with Lynch syndrome.
Georgeson P; Walsh MD; Clendenning M; Daneshvar S; Pope BJ; Mahmood K; Joo JE; Jayasekara H; Jenkins MA; Winship IM; Buchanan DD
Mol Genet Genomic Med; 2019 Jul; 7(7):e00781. PubMed ID: 31162827
[TBL] [Abstract][Full Text] [Related]
40. "Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation.
Kruse R; Rütten A; Hosseiny-Malayeri HR; Bisceglia M; Friedl W; Propping P; Ruzicka T; Mangold E
J Invest Dermatol; 2001 Mar; 116(3):463-5. PubMed ID: 11231323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
